Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese-Language Podcast: ESMO上的中国数据

Plus, mRNA and inhaled COVID vaccines, exec moves

Executive Summary

Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.

China Biotech Podcast host Brian Yang talks to special guest Annie Siu, Citeline's director of content for APAC, with a focus on the recent European Society for Medical Oncology (ESMO) Congress 2022, in the latest edition of this Chinese-language podcast.

They discuss Citeline's on-the-ground coverage of ESMO and highlight immuno-oncology data readouts from two major Chinese developers, Jiangsu Hengrui Medicine Co., Ltd. and BeiGene, Ltd. in advanced hepatocellular carcinoma. (Also see "ESMO: Positive Results Buoy Chinese Oncology Developers' Global Hopes" - Scrip, 11 Sep, 2022.)

In particular, the current situation for HCC in China, such as incidence and mortality, and current treatment options for advanced patients, are looked at, along with treatment guidelines and recommendations.

In the second part of the podcast, Brian talks to Scrip's Shanghai-based senior reporter Dexter Yan about mRNA vaccine developments in China. (Also see "New Front-Runner Emerges In China mRNA Booster Race" - Scrip, 25 Aug, 2022.)

Also on the agenda are the first approval of an inhaled COVID-19 vaccine from CanSino Biologics Inc.  (Also see "China Approves World’s First Inhaled COVID-19 Vaccine" - Scrip, 9 Sep, 2022.), as well as recent executive moves at Everest Medicines Limited.

欢迎来到新一期的中国生物制药播客。

本期节目有幸请到Citeline亚太内容总监Annie Siu博士来谈刚刚举办的欧洲肿瘤内科学会(ESMO)年会和中国公司的数据。其中,江苏恒瑞和百济神州的PD-1单抗针对肝癌(HCC)的研究数据。

此外,中国的肝癌发病率和死亡率,以及目前的治疗手段,CSCO和卫健委的治疗指南也是话题之一。

在后半部分,我们讨论了mRNA疫苗开发的现状,和康希诺第一个吸入剂型新冠疫苗在国内的获批,以及最近的云顶新耀的高管人事变动。

如果你有任何建议,意见和希望我们讨论的话题,请发电邮联系我们。

我们往期的播客都可以在喜马拉雅和SoundCloud上下载收听。

Annie Siu的分享细节如下:

我们Citeline, Biomedtracker和Datamonitor Healthcare的同事一直关注中国药企在国际会议上发布的信息。ESMO是我们关注的其中一个临床相关的国际会议。会议期间,我们会特派Oncology team 的同事整合会议中的口头报告和Poster中公布的新闻、临床结果,然后收录到我们数据库当中,例如,我们的Trialtrove 过去已经从不同ESMO相关的会议中收集并更新了9000多项临床试验档案。每年我们Biomedtracker和Datamonitor Healthcare的同事更会在会议前发布Planner,会后的总结报告,和定时发布相关适应症的市场分析报告。我相信很多听众也看过我们的报告。

今年我们分别于八月和九月发表了肝细胞癌的市场分析报告和ESMO 2022 planner,之后我们Biomedtracker的同事还会有一个总结ESMO 2022 的podcast,大家一定要注意哦!

我今天特别选了肝细胞癌的市场分析和中国药企在ESMO 2022发表的两个Late breaking abstracts 报告和大家分享,他们的口头报告也分享了PD-1 inhibitor对不可切除的肝细胞癌的临床结果。LBA35 是由南京金陵医院秦叔逵教授主讲,题目是“卡瑞利珠单抗联合阿帕替尼一线治疗晚期肝细胞癌的全球多中心、随机对照Ⅲ期研究”。这项研究由全球13个国家和地区的95家研究中心共同参与,543例患者入组,大概一半入组卡瑞利珠单抗+阿帕替尼组,我们说的双艾组合,另外一半患者入组对照组,接受索拉非尼的治疗。另一个PD-1 inhibitor,正是BeiGene的替雷利珠单抗,作为单药使用,同样对比索拉非尼。这个Rationale-301的临床是一项全球三期的临床,674位来自亚洲、欧洲和美国的患者参与。

2022年2月,国家癌症中心发布了最新一期的全国癌症统计数据。全国肿瘤登记中心负责全国肿瘤登记数据收集、质量控制、汇总、分析及发布工作。这次报告发布数据为全国487个肿瘤登记中心收集汇总的2016年数据。数据显示肝癌,以新发病例计算是第四位,以死亡人数计算是第二位。大家都知道肝癌中,HCC 大约占病例的 80%,最常见于亚洲。

我国中国临床肿瘤学会(CSCO)和国家卫生健康委员会(NHC)均发布相关指南。当中也有一些与海外NCCN指南相同,例如索拉非尼、仑伐替尼、阿替利珠单抗联合贝伐珠单抗、等。但也有一些是中国独有的,例如:多纳非尼、信迪利单抗联合贝伐珠单抗生物类似物、等。一线不可切除HCC 的市场竞争可能会越来越激烈,Trialtrove的分析结果显示各种monotherapy或combination 的系统抗肿瘤治疗的临床试验正在中国或全球开展。部分药企更扩展到局部中期HCC患者中,或与TACE联用,我们期待相关临床的结果。


 

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel